What does the evidence say about Calcium Bone Turnover Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Calcium Bone Turnover Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - The therapeutic diet emphasized a lower phosphorus-to-protein ratio, higher plant-based content, and increased fiber. [Peng YS (2026); evidence level 2] - The therapeutic diet significantly increased BAP levels after 7 days (median difference: + 0.8 μg/L, P = 0.02), but did not alter other markers. [Peng YS (2026); evidence level 2] - Bone turnover abnormalities are common in patients undergoing hemodialysis and contribute to fracture, vascular calcification, and mortality. [Peng YS (2026); evidence level 2] - Although therapeutic diets targeting phosphate balance improve mineral metabolism, their short-term effects on bone turnover remain unclear. [Peng YS (2026); evidence level 2] - Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. [Ahmad Areeb (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.